Workflow
Exact Sciences(EXAS) - 2024 Q2 - Quarterly Report
EXASExact Sciences(EXAS)2024-07-31 21:06
Transcript
Slide

Revenue and Financial Performance - Revenue for the three months ended June 30, 2024, was 699.3million,anincreaseof699.3 million, an increase of 77.2 million compared to the same period in 2023, while the loss from operations decreased by 50.7million[179].−Thecompanyreportedtotalrevenueof50.7 million [179]. - The company reported total revenue of 699.3 million for the three months ended June 30, 2024, an increase of 12.4% from 622.1millioninthesameperiodof2023[192].−Screeningrevenueincreasedto622.1 million in the same period of 2023 [192]. - Screening revenue increased to 531.6 million for the three months ended June 30, 2024, up from 462.8millionin2023,drivenbygrowthincompletedCologuardtests[192].−PrecisionOncologyrevenueroseto462.8 million in 2023, driven by growth in completed Cologuard tests [192]. - Precision Oncology revenue rose to 167.7 million for the three months ended June 30, 2024, compared to 157.2millionin2023,attributedtoincreaseddemandforOncotypeDXtests,particularlyinJapan[192].−Thecompanyincurredanaccumulateddeficitofapproximately157.2 million in 2023, attributed to increased demand for Oncotype DX tests, particularly in Japan [192]. - The company incurred an accumulated deficit of approximately 3.60 billion as of June 30, 2024, and expects to continue incurring net losses in the near future [190]. - Cash provided by operating activities was 107.1millionforthethreemonthsendedJune30,2024,animprovementof107.1 million for the three months ended June 30, 2024, an improvement of 6.6 million compared to the same period in 2023 [179]. - Net cash provided by operating activities was 24.8millionforthesixmonthsendedJune30,2024,comparedto24.8 million for the six months ended June 30, 2024, compared to 62.2 million for the same period in 2023 [212]. - Cash used in investing activities increased by 468.0millionforthesixmonthsendedJune30,2024,comparedtocashprovidedbyinvestingactivitiesforthesameperiodin2023[214].−Proceedsfromtheissuanceofconvertiblenoteswere468.0 million for the six months ended June 30, 2024, compared to cash provided by investing activities for the same period in 2023 [214]. - Proceeds from the issuance of convertible notes were 266.8 million in the second quarter of 2024, compared to 138.0millioninthefirstquarterof2023[215].−AsofJune30,2024,thecompanyhadoutstandingaggregateprincipalof138.0 million in the first quarter of 2023 [215]. - As of June 30, 2024, the company had outstanding aggregate principal of 249.2 million on its convertible notes maturing on January 15, 2025 [219]. Product Development and Innovation - Exact Sciences secured an exclusive license to TwinStrand Bioscience Inc.'s patented technologies, enhancing its product development capabilities [179]. - The company is focused on advancing new tests in colorectal cancer screening, MRD, and multi-cancer screening, with plans to obtain FDA approval for Cologuard Plus [186]. - The Cologuard Plus test demonstrated an overall sensitivity of 94% for colorectal cancer at a specificity of 91%, representing a 30% relative improvement compared to previous tests [182]. - The multi-cancer screening (MCS) test, branded as Cancerguard, showed a mean sensitivity of 61% and mean specificity of 98.2% for detecting cancer signals from 15 organ sites [182]. - Research and development expenditures are expected to remain a significant portion of operating expenses as the company enhances its product portfolio [183]. - Research and development expenses increased to 120.9millionforthethreemonthsendedJune30,2024,upfrom120.9 million for the three months ended June 30, 2024, up from 104.1 million in 2023, primarily due to a 25.8millionexpensefromtheterminationofalicenseagreement[197].MarketExpansionandAccess−Over1millionpeoplewerescreenedwiththeCologuardtestinasinglequarterforthefirsttime[179].−Thecompanyplanstoexpandscreeningaccesstounderservedpopulations,aimingtotestmoreindividualsandgeneratesustainableprofits[187].−ThecompanyhasprovidedOncotypetestsinapproximately120countriesoutsideoftheU.S.,expandingitsinternationalmarketpresence[180].−ThecompanysecuredreimbursementfortheOncotypeDXtestinJapan,potentiallyimpactingover100womenperdaywithearly−stagebreastcancer[189].ExpensesandFinancialManagement−TotalcostofsalesforthethreemonthsendedJune30,2024,was25.8 million expense from the termination of a license agreement [197]. Market Expansion and Access - Over 1 million people were screened with the Cologuard test in a single quarter for the first time [179]. - The company plans to expand screening access to underserved populations, aiming to test more individuals and generate sustainable profits [187]. - The company has provided Oncotype tests in approximately 120 countries outside of the U.S., expanding its international market presence [180]. - The company secured reimbursement for the Oncotype DX test in Japan, potentially impacting over 100 women per day with early-stage breast cancer [189]. Expenses and Financial Management - Total cost of sales for the three months ended June 30, 2024, was 189.8 million, an increase of 20.9% from 157.0millionin2023,drivenbyhigherproductioncostsandpersonnelexpenses[196].−Generalandadministrativeexpensesdecreasedto157.0 million in 2023, driven by higher production costs and personnel expenses [196]. - General and administrative expenses decreased to 201.9 million for the three months ended June 30, 2024, compared to 238.0millionin2023,mainlyduetoreducedprofessionalandlegalfees[201].−Thecompanyanticipatesthatsalesandmarketingexpenseswillgenerallyincreaseinfutureperiodsasitinvestsinhigh−impactopportunitieswhiledecreasingasapercentageofrevenueovertime[198].−Impairmentoflong−livedassetswas238.0 million in 2023, mainly due to reduced professional and legal fees [201]. - The company anticipates that sales and marketing expenses will generally increase in future periods as it invests in high-impact opportunities while decreasing as a percentage of revenue over time [198]. - Impairment of long-lived assets was 8.2 million and 12.6millionforthethreeandsixmonthsendedJune30,2024,respectively,comparedto12.6 million for the three and six months ended June 30, 2024, respectively, compared to 0.6 million for the same periods in 2023 [202]. Other Financial Metrics - Investment income, net increased to 11.8millionforthethreemonthsendedJune30,2024,comparedto11.8 million for the three months ended June 30, 2024, compared to 4.8 million for the same period in 2023, and to 18.0millionforthesixmonthsendedJune30,2024,comparedto18.0 million for the six months ended June 30, 2024, compared to 5.3 million for the same period in 2023 [204]. - Net interest income was 0.1millionforthethreemonthsendedJune30,2024,comparedtointerestexpenseof0.1 million for the three months ended June 30, 2024, compared to interest expense of 7.8 million for the same period in 2023 [205]. - Income tax expense increased to 1.5millionforthethreemonthsendedJune30,2024,comparedto1.5 million for the three months ended June 30, 2024, compared to 1.1 million for the same period in 2023 [206]. - Other operating income was 3.8millionand3.8 million and 3.5 million for the three and six months ended June 30, 2024, compared to zero for the same periods in 2023 [203].